system, (application history system data and documentation will be preserved).

5. Department of Justice (N1–60–96–5). Records maintained by the Legal Support Unit, Criminal Division, relating to requests for authorization to conduct grand jury proceedings and take other legal actions.

6. Department of Justice (N1–60–96–7). Documents submitted voluntarily or under subpoena to the Criminal Division that are not used in litigating the case for which they were obtained.

7. Department of Labor (N1–174–96–6). Revisions to the comprehensive schedule for the Office of Public Affairs.

8. Department of the Treasury, Bureau of Alcohol, Tobacco, and Firearms (N1–436–93–1). Ad hoc management reports generated by the National Firearms Registration and Transfer Record, (the master file for this system is designated for preservation).

9. Department of the Treasury, Bureau of Alcohol, Tobacco, and Firearms (N1–436–96–7). Firearms Technology Branch technical determinations.

10. Federal Deposit Insurance Corporation (N1–034–95–2). Records relating to the resolution of failed financial institutions.

Dated: September 27, 1996.

James W. Moore,

Assistant Archivist for Records Administration.

[FR Doc. 96–25567 Filed 10–4–96; 8:45 am]

BILLING CODE 7515–01–M

NATIONAL SCIENCE FOUNDATION

Advisory Panel for Cell Biology; Notice of Meeting

In accordance with the Federal Advisory Committee Act (Pub.L. 92–463, as amended), the National Science Foundation announces the following meeting.

Name: Advisory Panel for Cell Biology (1136)—(Panel A).

Date and Time: October 23–25, 1996, 8:30 a.m. to 6:00 p.m.

Place: Room 380, National Science Foundation, 4201 Wilson Boulevard, Arlington, VA 22230.

Type of Meeting: Closed.

Contact Persons: Dr. Barbara Zain, Program Director for the Cell Biology Program, National Science Foundation, Room 655 South, Arlington, VA 22230. Telephone: 703/306–1442.

Purpose of Meeting: To provide advice and recommendations concerning proposals submitted to NSF for financial support.

Agenda: To review and evaluate research proposals submitted to the Signal Transduction Program as part of the selection process for awards.

Reason for Closing: The proposals being reviewed include information of a proprietary or confidential nature, including technical information; financial data, such as salaries and personal information concerning individuals associated with the proposals. These matters are exempt under 5 U.S.C. 552b(c) (4) and (6) of the Government in the Sunshine Act.

Dated: October 1, 1996.

M. Rebecca Winkler,

Committee Management Officer.

[FR Doc. 96–25619 Filed 10–4–96; 8:45 am]

BILLING CODE 7555–01–M

NEIGHBORHOOD REINVESTMENT CORPORATION

Sunshine Act Meeting; Regular Meeting of the Board of Directors

TIME & DATE: 2:00 P.M., Thursday, October 17, 1996.

PLACE: Neighborhood Reinvestment Corporation, 1325 G Street, N.W., Suite 800, Board Room, Washington, D.C. 20005.

STATUS: Open.

CONTACT PERSON FOR MORE INFORMATION: Jeffrey T. Bryson, General Counsel/Secretary, 202/376–2441.

AGENDA:

I. Call to Order
II. Approval of Minutes: July 31, 1996, Regular Meeting
III. Treasurer's Report
IV. Executive Director's Quarterly Management Report
V. Adjourn

Jeffery T. Bryson,

General Counsel/Secretary.

[FR Doc. 96–25819 Filed 10–3–96; 3:34 pm]

BILLING CODE 7570–01–M

NUCLEAR REGULATORY COMMISSION

Agency Information Collection Activities: Proposed Collection; Comment Request

AGENCY: U. S. Nuclear Regulatory Commission (NRC).

ACTION: Notice of pending NRC action to submit an information collection request to OMB and solicitation of public comment.

SUMMARY: The NRC is preparing a submittal to OMB for review of continued approval of information collections under the provisions of the Paperwork Reduction Act of 1995 (44 U.S.C. Chapter 35).

Information pertaining to the requirement to be submitted:

1. The title of the information collection: 10 CFR 35.32 and 35.33 ''Quality Management Program and Misadministrations''.

2. Current OMB approval number: 3150–0171.

3. How often the collection is required: For quality management program (QMP):

Reporting: One time submittal of a quality management program (QMP) for each existing and new licensee, when the QMP is modified, or when new modalities (uses) are added to an existing license.

Ten Agreement States, who should have adopted the rule by January 1995, have not done so. Therefore, this estimate includes the one-time burden for the development of QMPs by these ten Agreement State licensees.

Recordkeeping: Records of written directives, administered dose or dosage, annual review, and recordable events, for 3 years.

For Misadministrations:

Reporting: Whenever a misadministration occurs.

Recordkeeping: Records of misadministrations for 5 years.

4. Who is required or asked to report: NRC Part 35 licensees who use byproduct material in limited diagnostic and therapeutic ranges and similar type of licensees regulated by Agreement States.

5. The number of respondents: 6300 licensees.

6. The number of hours needed annually to complete the requirement or request: 34,743 hours for applicable licensees (24,400 hrs/yr for reporting and 10,343 hrs/yr for recordkeeping).

7. Abstract: In the medical use of byproduct material, there have been instances where byproduct material was not administered as intended or was administered to a wrong individual, which resulted in unnecessary exposures or inadequate diagnostic or therapeutic procedures. The most frequent causes of these incidents were: insufficient supervision, deficient procedures, failure to follow procedures, and inattention to detail. In an effort to reduce the frequency of such events, the NRC requires licensees to implement a quality management program (§ 35.32) to provide high confidence that byproduct material or radiation from byproduct material will be administered as directed by an authorized user physician.

Collection of this information enables the NRC to ascertain whether misadministrations are properly identified, evaluated, and investigated by the licensee and that corrective action is taken. Additionally, NRC has a responsibility to inform the medical community of generic issues identified